Even if it has been recently shown in a large cohort of AML patients that its poor prognosis is independent from the EVI1 spliceoform expressed [17], the poor impact of the EVI1+/1D has always been confirmed and should be relevant for stratifying patients in therapeutic protocols. The gene discussed is MECOM; the disease is acute myeloid leukemia.